Across TCGA pan-cancer cohorts, FCAR mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FCAR data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FCAR mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FCAR expression acts as an unfavorable survival marker.

PDAC, LUAD, and HNSC are the cancer types where FCAR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.294	0.783	<.001	46	view →
LUAD	DFS	Tertile	III,IV	0.380	1.000	.006	20	view →
HNSC	DFS	Median	III,IV	0.466	0.697	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: FCAR tumor-vs-normal RNA expression · all FCAR data types